Showing posts with label Yaz Study. Show all posts
Showing posts with label Yaz Study. Show all posts

Monday, January 28, 2013

Just How Safe is Yaz? Women Need to Know!


The oral contraceptive Yasmin was released in 2001 by the pharmaceutical company Bayer, followed byYaz in 2006. They differ from other birth control pills in the synthetic progesterone they utilize, drospirenone, which is marketed as less likely to cause weight gain and bloating than other birth control pills. Yaz soon became the most popular birth control pill in the U.S., due in part to a widespread advertising campaign promoting the drug as what theNew York Times dubbed “a quality of life treatment,” claiming it could also clear up acne, prevent bloating and ease the depression and anxiety associated with both PMS and the controversial condition of PMDD. It prevents pregnancy at the same rate of effectiveness as all other oral contraceptives.
In 2009, the FDA requested that Bayer distribute a corrective advertisement to counter its aggressively screened commercials that were said to be making misleading assertions about the capabilities of the drug, promoting it for unapproved uses and making light of the more serious health risks (such as blood clots). However, in 2010 the drug remained the second-best-selling Bayer product, bringing in $1.5 billion in sales.
As of January 2012, there are approximately 10,000 lawsuits against Bayer by women who have suffered blood clots and by the families of those women who have died whilst taking Yaz or Yasmin. It is considered the most complained-about drug on the Internet, with thousands of women voicing concerns in online forums and support groups over health issues both physical and emotional. Jane Bennett and Alexandra Pope, authors of The Pill: Are You Sure It’s for You?, characterize many of these problems as “quality-of-life-threatening.” I have written extensively on my own experience with Yasmin in my blog, Sweetening the Pill, and for the UK Independent and have been quoted in Fabulous magazine the Washington Post. 
Two studies conducted with funding from Bayer revealed that Yaz and Yasmin held no higher risk of blood clots than other birth control pills. However, last month it was revealed that five other studies undertaken independent of Bayer suggested a 50-to-75 percent increased risk of clots for those taking these birth control pills in comparison to others. A former FDA commissioner, David Kessler, charged that Bayer deliberately withheld data about this early on in order to push through the drugs’ approvals. In response, the FDA called an advisory committee to evaluate the safety of birth control pills containing drospirenone. The decision had the potential to cause the drugs to be pulled off the market, but the panel voted by a four-person margin that the drugs’ benefit outweighed the risks.
Yet a government watchdog group, the Project on Government Oversight (POGO), conducted an independent investigation that revealed three of the advisors on the FDA panel had research or other financial ties to Bayer. A fourth advisor was connected to manufacturing the generic version of these pills. All four voted for Yaz and Yasmin to continue to be prescribed by doctors. POGO asked the FDA that a new advisory committee be brought together to make another assessment.
Should these developments impact women’s perspective on the birth control pill? Should we consider that use of the Pill for pregnancy prevention, let alone acne or PMS, is still today, as women’s health activist Barbara Seaman wrote in her 1969 book The Doctors’ Case Against the Pill, “like tinkering with nuclear bombs to fight off the common cold”?
Says Ms. blogger Elizabeth Kissling, professor of communication and women’s and gender studies at Eastern Washington University and past president of the Society for Menstrual Cycle Research:
I’m surprised there has not been a broader call for more research, or wider public discussions of the risks of this pill. When a drug company is withholding data and 10,000 lawsuits are pending, more than research is needed. I can’t help but wonder why we’re not seeing Congressional hearings–akin to the 1970 Nelson Pill Hearings–again, and more of an outcry from both physicians and patients.
Much of the media coverage of these recent developments and research was quick to assert the unimportance of women’s concerns. It was repeatedly reported that, when compared to the risk of blood clot development associated with pregnancy, the risk produced by taking any oral contraceptive–including Yasmin or Yaz–is of little concern. This is misleading in that it suggests there are only two states in which young women can choose to live: on birth control pills or pregnant. The fear has been voiced that any discussion of the negative impact of the Pill will prompt women to come off of it and fall unintentionally pregnant. No coverage that this writer has read discussed a comparison with non-hormonal contraceptive alternatives–which, of course, hold no increased risk of blood clots. Some of these alternatives are just as effective in preventing pregnancy as oral contraceptives, and others are more so.
According to Laura Wershler, veteran pro-choice sexual and reproductive health advocate and board director of the Canadian Federation for Sexual Health,
We need to reframe the idea that hormonal birth control is the gold standard of contraception. If women are quitting the Pill, and they have every right to do so, and they are not using alternative methods of birth control effectively, that’s proof positive that what we are teaching about contraception is incomplete and ineffective. If we make the Pill the ‘right’ choice, then why should we be upset when women stop taking it and get pregnant?
It is often claimed within news stories that the Pill “regulates” a woman’s menstrual cycle, when it, in fact, stops and replaces the cycle. All of this propaganda for the Pill is extremely misleading, and it further breeds a lack of confidence to know that Bayer paid women’s magazines to advocate for Yaz. Such actions blind women to their choices and to understanding how their bodies work. There is much research that supports the health benefits of consistent (typically monthly) ovulation, which can be found through the Centre for Menstrual Cycle and Ovulation Research.
The absence of education in body literacy is a major factor in unwanted pregnancies. However, this lack of education is beneficial to some: It helps sustain the billion-dollar profits of pharmaceutical companies.
Photo is the cover of The Pill: Are You Sure It’s for You?

Legal Help for Victims of the Side Effects of Yaz - Yaz Lawyers

If you or someone you love took Yaz and suffered from serious side effects, including deep vein thrombosis, pulmonary embolism, stroke, heart attack, or hyperkalemia, you have valuable legal rights.  Please fill out our online form, or call (1-888-925-3852) to discuss your case with a Yaz attorney.

Wednesday, January 23, 2013

Current Yasmin and Yaz Label Warnings Are Inadequate


Seated around a U-shaped configuration of tables sat the 26 member FDA Advisory Committee — all scientists or physicians gathered to discuss the risks of birth control pills containing DRSP. They focused on the risks as described in recent studies, including the FDA’s own study that looked at over 800,000 women during a six year time period. The results of the FDA study concluded that new users of Yasmin may be twice as likely to experience a blood clot as users of other birth control pills containing the progestin Levonorgestrel.
During the first two hours of the hearing, an FDA representative presented an overview of the studies Bayer conducted after Yasmin was introduced to the market. The Bayer studies suggested that Yaz posed little additional risk. Then an FDA-paid scientist presented the results of the study that she conducted, showing a greater risk. But rather than bolstering her results with the six independent studies also showing a greater risk, the FDA-paid scientist gave those other studies – including those done by Drs. Jick of the U.S., Parkin of the U.K. ,Vlieg from the Netherlands and Lidegaard of Denmark– short shrift. Rather she focused on trying to explain away the conflicting results between the FDA’s own study and the Bayer-sponsored studies. Possible explanations she offered: FDA study design weaknesses and channeling. (Channeling is the selective prescribing of Yasmin to high-risk patients such as women with polycystic ovary syndrome.)
The FDA teed up nicely the topics for more than two hours of presentations by the German- owned Bayer representatives. Flanked by more than thirty Bayer suits seated neatly in five rows, Bayer’s vice president of US Medical Affairs, Leo Pouffle, with his stunted German accent led the charge. A regimen of six head-set tethered technicians each peering over his or her laptop supplied Dr. Poufle and other Bayer speakers with plenty of power-point ammunition. Bayer’s well-rehearsed battalion calmly, courteously and methodically casted doubt on the FDA study.
Members of the public were then allowed to speak. Each was limited to three minutes. Family members of Yaz victims described how Bayer robbed them of their young, fit, active healthy daughters who died after suffering a pulmonary embolism – caused by taking Yasmin or Yaz. Members of other women’s health organizations spoke up about the unnecessary health risks posed by DRSP. Two scientists testified, including Bert Gerstman, an epidemiologist who criticized the design of Bayer’s studies. Unfortunately, the public comment had little effect on today’s outcome.
After two more hours of questions and answers about the studies, the FDA advisory committee decided that Bayer’s current labels do not adequately reflect the risk/benefit profile for these products. That was expected, since the results of the FDAs own study are not described in the current warnings. But to the disappointment of consumer advocates, the committee did not push for black box or even tougher warnings. The members merely recommended that the FDA draft simpler warnings with an updated summary of recent conflicting study results.
One FDA committee member pressed Bayer’s vice president of US Medical Affairs on whether Yasmin and Yaz are more effective than other oral contraceptives at preventing pregnancy. If the drug was more effective, that might justify their higher level of risk. Dr. Plouffe deflected the question twice. But when the committee asked a third time, he admitted that Yasmin and Yaz are no more effective that other combination oral contraceptives.
Nonetheless, the committee voted 15 to 11 that the benefits of Bayer’s DRSP-containing oral contraceptives outweigh their risks. Apparently, some committee members, mostly clinicians, needed no evidence that Yasmin and Yaz are more effective than other oral contraceptives to come to that conclusion. They were satisfied that Yasmin and Yaz are as effective as other oral contraceptives at preventing birth and refused to accept reported results that Yasmin and Yaz pose greater risks of VTE than other birth control pills. More sympathetic to the consumer’s plight, the scientist and epidemiologists on the committee were dissatisfied with Bayer’s studies and offered their opinions that Yaz and Yasmin posed risks that were simply unacceptable.

Legal Help for Victims of the Side Effects of Yaz - Yaz Lawyers

If you or someone you love took Yaz and suffered from serious side effects, including deep vein thrombosis, pulmonary embolism, stroke, heart attack, or hyperkalemia, you have valuable legal rights.  Please fill out our online form, or call (1-888-925-3852) to discuss your case with a Yaz attorney.

Sign-up for FREE daily Updates.
Twitter Delicious Facebook Digg Stumbleupon Favorites More

 
Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Powerade Coupons